Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer

By          

Oncology Reports, Vol. 28, Iss. 2, 2012-01 ,pp. : 721-727

Spandidos Publications

Access to resources Recommend Favorite

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG0803)

By Wu Y.-L.   Zhou C.   Cheng Y.   Lu S.   Chen G.-Y.   Huang C.   Huang Y.-S.   Yan H.-H.   Ren S.   Liu Y.   Yang J.-J.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 993-999

Oxford University Press

Access to resources Recommend Favorite

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

By            

Oncology Reports, Vol. 28, Iss. 3, 2012-01 ,pp. : 763-767

Spandidos Publications

Access to resources Recommend Favorite

Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

By Kalmadi Sujith   McNeill Giles   Davis Mellar   Peereboom David   Adelstein David   Mekhail Tarek  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 507-513

Humana Press, Inc

Access to resources Recommend Favorite

Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer - a phase II trial

By Laack E.   Mende T.   Benk J.   Chemaissani A.   Scholtze J.   Lorenz C.   Niestroy A.   Dalhoff K.   Muller T.   Walter T.   Durk H.   Edler L.   Hossfeld D.K.  

European Journal of Cancer, Vol. 37, Iss. 5, 2001-03 ,pp. : 583-590

Elsevier

Access to resources Recommend Favorite